The Novel Nonsteroidal and Selective Mineralocorticoid Receptor Antagonist Finerenone Differentiates from SGLT2 Inhibitor Empagliflozin by Anti-Fibrotic Effects in a Progressive Mouse Kidney Fibrosis Model - Droebner, K; Pavkovic, M; Grundmann, M
ASN Kidney Week 2020 Reimagined; 22.10.2020